Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W
Record ID 32013000633
English
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hta.ac.uk/erg/supplements/supplement1401.pdf#nameddest=article10
URL for additional information:
http://www.hta.ac.uk/1903
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Cost-Benefit Analysis
- Models, Economic
- Quality of Life
- Quality-Adjusted Life Years
- Survival
- Antimetabolites, Antineoplastic
- Azacitidine
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Myelodysplastic Syndromes
- Enzyme Inhibitors
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.